Correction: Ran et al. Nomogram for Predicting Recurrence-Free Survival of Primary Localized Gastrointestinal Stromal Tumor. J. Pers. Med. 2023, 13, 498
Variable | RFS | |||
---|---|---|---|---|
Univariate | Multivariate | |||
HR (95% CI) | p Value | HR (95% CI) | p Value | |
Age at diagnosis (years) | 0.99 (0.98–1.01) | 0.575 | - | |
Tumor size (cm) | 1.19 (1.13–1.25) | <0.001 | 1.16 (1.09–1.24) | <0.001 |
Ki-67 Li (%) | 1.04 (1.02–1.07) | <0.001 | 1.01 (0.97–1.05) | 0.519 |
Gender | 0.002 | 0.003 | ||
Male | 1.0 (ref) | 1.0 (ref) | ||
Female | 0.47 (0.30–0.75) | 0.49 (0.30–0.78) | ||
Residence | 0.521 | - | ||
City | 1.0 (ref) | |||
Rural township | 1.18 (0.71–1.94) | |||
Initial symptom | 0.380 | - | ||
Asymptomatic | 1.0 (ref) | |||
Hematemesis | 0.71 (0.10–5.36) | |||
Hematochezia | 0.90 (0.42–1.90) | |||
Abdominal discomfort | 1.60 (0.93–2.78) | |||
Sour regurgitation | 0.00 (0.00–1.94) | |||
Eating obstruction | 1.93 (0.45–8.32) | |||
Mitotic counts (per 50 HPFs) | <0.001 | 0.016 | ||
N ≤ 5 | 1.0 (ref) | 1.0 (ref) | ||
5 < N ≤ 10 | 1.49 (0.84–2.64) | 1.30 (0.68–2.49) | ||
N > 10 | 4.79 (2.76–8.33) | 3.00 (1.39–6.50) | ||
Tumor site | 0.002 | 0.608 | ||
Stomach | 1.0 (ref) | 1.0 (ref) | ||
Small intestine | 2.54 (1.53–4.20) | 1.43 (0.82–2.50) | ||
Colorectum/rectal Other | 0.54 (0.07–3.98) | 0.82 (0.11–6.22) | ||
2.60 (1.05–6.39) | 1.49 (0.58–3.83) | |||
CD34 | 0.362 | - | ||
Negative | 1.0 (ref) | |||
Positive | 0.76 (0.43–1.37) | |||
CD117 | 0.238 | - | ||
Negative | 1.0 (ref) | |||
Positive | 0.55 (0.20–1.49) | |||
DOG-1 | <0.001 | 0.018 | ||
Negative | 1.0 (ref) | 1.0 (ref) | ||
Positive | 0.29 (0.18–0.49) | 0.52 (0.30–0.89) | ||
Gene mutation | 0.990 | |||
KIT exon 11 | 1.0 (ref) | |||
KIT exon 9 | 1.06 (0.61–1.82) | |||
PDGFR-α | 1.14 (0.28–4.72) | |||
Wild type | 1.22 (0.58–2.59) | |||
Other | 0.00 (0.00–5.60) | |||
Neoadjuvant therapy with imatinib | 0.280 | - | ||
Not received | 1.0 (ref) | |||
Received | 0.46 (0.11–1.88) | |||
Adjuvant therapy with imatinib | <0.001 | <0.001 | ||
Not received | 1.0 (ref) | 1.0 (ref) | ||
Drug discontinuance | 0.28 (0.15–0.53) | 0.33 (0.17–0.64) | ||
Drug continuance | 0.22 (0.13–0.37) | 0.19 (0.11–0.32) |
Reference
- Ran, P.; Tan, T.; Zhou, H.; Li, J.; Yang, H.; Li, J.; Zhang, J. Nomogram for Predicting Recurrence-Free Survival of Primary Localized Gastrointestinal Stromal Tumor. J. Pers. Med. 2023, 13, 498. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ran, P.; Tan, T.; Zhou, H.; Li, J.; Yang, H.; Li, J.; Zhang, J. Correction: Ran et al. Nomogram for Predicting Recurrence-Free Survival of Primary Localized Gastrointestinal Stromal Tumor. J. Pers. Med. 2023, 13, 498. J. Pers. Med. 2024, 14, 819. https://doi.org/10.3390/jpm14080819
Ran P, Tan T, Zhou H, Li J, Yang H, Li J, Zhang J. Correction: Ran et al. Nomogram for Predicting Recurrence-Free Survival of Primary Localized Gastrointestinal Stromal Tumor. J. Pers. Med. 2023, 13, 498. Journal of Personalized Medicine. 2024; 14(8):819. https://doi.org/10.3390/jpm14080819
Chicago/Turabian StyleRan, Pan, Tao Tan, Hui Zhou, Jinjin Li, Hao Yang, Juan Li, and Jun Zhang. 2024. "Correction: Ran et al. Nomogram for Predicting Recurrence-Free Survival of Primary Localized Gastrointestinal Stromal Tumor. J. Pers. Med. 2023, 13, 498" Journal of Personalized Medicine 14, no. 8: 819. https://doi.org/10.3390/jpm14080819
APA StyleRan, P., Tan, T., Zhou, H., Li, J., Yang, H., Li, J., & Zhang, J. (2024). Correction: Ran et al. Nomogram for Predicting Recurrence-Free Survival of Primary Localized Gastrointestinal Stromal Tumor. J. Pers. Med. 2023, 13, 498. Journal of Personalized Medicine, 14(8), 819. https://doi.org/10.3390/jpm14080819